Literature DB >> 24980882

Episodic nature of symptoms in irritable bowel syndrome.

Olafur S Palsson1, Jeffrey Baggish2, William E Whitehead1.   

Abstract

OBJECTIVES: The objectives of this study were to determine whether the symptoms of diarrhea (defined as loose or watery stools), constipation (hard or lumpy stools), abdominal pain, and bloating occur in episodes rather than sporadically in patients with irritable bowel syndrome (IBS); to identify rules for defining the onset and termination of symptom episodes; and to assess the overlap of these episodes.
METHODS: IBS patients kept a symptom log in which they rated the consistency of each bowel movement (BM) on the Bristol Stool Scale for 3 months. Each night they transferred these data to an internet website and also rated abdominal pain and bloating for that day. Data were analyzed for 124 patients who completed at least 21 consecutive diary days (mean of 73 days) without taking laxative, antidiarrheal, or IBS-specific medications. For each symptom in each patient, we computed the correlation between consecutive observations (autocorrelations) in the diary to determine whether the symptom tended to occur in clusters of several instances, as would happen in episodes vs. happening randomly. Next, we compared different patterns by which diarrhea and nondiarrhea stools alternate to identify episode definitions that captured at least 75% of loose/watery stools. A similar pattern analysis was performed for constipation. Pain and bloating episodes were defined as days with an intensity rating >3 on a 0-10 scale. These patterns were converted into rules for defining the onset and termination of symptom episodes. Last, we used these episode definitions to examine the overlap of pain with episodes of diarrhea, constipation, and pain.
RESULTS: Significant (P<0.05) autocorrelations were found in the Bristol Stool Scale ratings of 69.4% of patients and in the daily abdominal pain and bloating ratings of 52.4% and 68.5% of patients, respectively. Defining a diarrhea episode as two or more loose/watery stools never separated by >1 nonloose/watery stool or by a day without a BM captured 76% of all loose/water stools. Defining constipation episodes as two or more hard/lumpy stools never separated by >1 nonhard/lumpy stool captured 80% of hard/lumpy stools. Sequences of 3 or more days without a BM were also defined as constipation episodes because they were strongly associated with hard stools. Average episode durations were 2.1 days for diarrhea, 4.5 days for constipation, 3.1 days for pain, and 3.5 days for bloating. Overlap analysis showed that only 41.6% of constipation episode days and 67.0% of diarrhea episode days were pain episode days. Bloating and pain coexisted on 59.1% of days on which either type occurred.
CONCLUSIONS: Loose/watery stools and hard/lumpy stools occur in well-defined episodes. Pain and bloating also occur in episodes, but contrary to the Rome criteria more than half of the pain episodes occur outside episodes of abnormal stool consistency.

Entities:  

Mesh:

Year:  2014        PMID: 24980882     DOI: 10.1038/ajg.2014.181

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.

Authors:  Octavian Alexea; Vlad Bacarea; Núria Piqué
Journal:  United European Gastroenterol J       Date:  2015-10-30       Impact factor: 4.623

Review 2.  The global impact of IBS: time to think about IBS-specific models of care?

Authors:  Maura Corsetti; Peter Whorwell
Journal:  Therap Adv Gastroenterol       Date:  2017-07-31       Impact factor: 4.409

3.  Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: Results of a Nationwide Population-Based Study.

Authors:  Eric D Shah; Christopher V Almario; Brennan M Spiegel; William D Chey
Journal:  Am J Gastroenterol       Date:  2020-02       Impact factor: 12.045

4.  Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.

Authors:  Lucio Gnessi; Vladimir Bacarea; Marius Marusteri; Núria Piqué
Journal:  BMC Gastroenterol       Date:  2015-10-30       Impact factor: 3.067

5.  Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population.

Authors:  Nimish Vakil; Margie Stelwagon; Elizabeth P Shea; Steve Miller
Journal:  United European Gastroenterol J       Date:  2015-08-06       Impact factor: 4.623

6.  Evaluation of Gelatin Tannate Against Symptoms of Acute Diarrhea in Pediatric Patients.

Authors:  Eren Çağan; Saime Ceylan; Şenay Mengi; Havva Hasret Çağan
Journal:  Med Sci Monit       Date:  2017-04-27

7.  Treatment Algorithm for Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome Derived from a Canadian National Survey and Needs Assessment on Choices of Therapeutic Agents.

Authors:  Yvonne Tse; David Armstrong; Christopher N Andrews; Alain Bitton; Brian Bressler; John Marshall; Louis W C Liu
Journal:  Can J Gastroenterol Hepatol       Date:  2017-02-08

Review 8.  Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice.

Authors:  Magnus Simren; Olafur S Palsson; William E Whitehead
Journal:  Curr Gastroenterol Rep       Date:  2017-04

9.  Early weaning stress induces chronic functional diarrhea, intestinal barrier defects, and increased mast cell activity in a porcine model of early life adversity.

Authors:  C S Pohl; J E Medland; E Mackey; L L Edwards; K D Bagley; M P DeWilde; K J Williams; A J Moeser
Journal:  Neurogastroenterol Motil       Date:  2017-06-01       Impact factor: 3.598

10.  Xyloglucan for the Treatment of Acute Gastroenteritis in Children: Results of a Randomized, Controlled, Clinical Trial.

Authors:  Cătălin Pleșea Condratovici; Vladimir Bacarea; Núria Piqué
Journal:  Gastroenterol Res Pract       Date:  2016-05-03       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.